AVAH vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AVAH's Piotroski F-Score of 5/9 indicates a borderline stable financial health, but the absence of an Altman Z-Score and a dangerously high Debt/Equity ratio of 152.32 signal severe financial distress risk. Despite strong revenue growth (22.2% YoY) and impressive earnings surprises (average +362.87% in last 4 quarters), the company trades at a premium valuation (P/E 18.68, Price/Book 147.02) with no dividend and negative ROE. Insider selling totaling $7.14M in 6 months further undermines confidence, while the stock has underperformed over the past 6 months despite a 3-year gain of 506.1%. The Graham Number of $0.63 suggests deep undervaluation, but the intrinsic value of $2.59 is not supported by current fundamentals, indicating the market prices in aggressive growth expectations.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AVAH vs MRK: Head-to-Head Comparison
This page compares Aveanna Healthcare Holdings Inc. (AVAH) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.